Jean Luc Harousseau

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial

Thierry Façon, Jean Yves Mary, Cyrille Hulin et al. · The Lancet · 2007 · 870 citations

Medicine, Hematology, Oncology +17

Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation

Brian G.M. Durie, Robert A. Kyle, Andrew R. Belch et al. · The Hematology Journal · 2003 · 425 citations

Medicine, Hematology, Internal Medicine +16

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

Shaji Kumar, Sergio Giralt, Edward A. Stadtmauer et al. · Blood · 2009 · 233 citations · Full text

Medicine, Hematology, Oncology +17

Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Laurent Garderet, Simona Iacobelli, Philippe Moreau et al. · Journal of Clinical Oncology · 2012 · 188 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial)

Michel Attal, Valérie Lauwers‐Cancès, Cyrille Hulin et al. · Blood · 2015 · 127 citations

Medicine, Hematology, Oncology +17